GLPG Galapagos NV

139.27
-1.84  -1%
Previous Close 141.11
Open 140.02
52 Week Low 112
52 Week High 274.03
Market Cap $9,088,002,850
Shares 65,254,562
Float 65,254,562
Enterprise Value $2,648,062,267
Volume 95,190
Av. Daily Volume 144,953
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Filgotinib (MANTA)
Inflammatory Bowel Disease
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
GLPG1690 - NOVESA
Systemic sclerosis
Phase 2
Phase 2
Phase 2 trial met primary endpoint - September 10, 2020.
Filgotinib
Non-infectious uveitis
Phase 2
Phase 2
Phase 2 trial enrolment has been paused due to COVID-19.
Filgotinib
Rheumatoid arthritis (RA)
CRL
CRL
CRL announced August 18, 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2
Phase 2
Phase 3 trial to be initiated later in 2020.
Filgotinib PENGUIN
Psoriatic arthritis
Phase 3
Phase 3
Phase 3 enrolment has been paused due to COVID-19,
Filgotinib - SELECTION
Ulcerative colitis
Phase 2/3
Phase 2/3
Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3
Phase 3
Phase 3 enrolment to be completed in 2021.
MOR106 IGUANA
Atopic dermatitis
Phase 2
Phase 2
Phase 2 trial halted due to futility - October 28, 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 2
Phase 2
Phase 2 trial did not meet primary endpoint.
GLPG3970
Psoriasis
Phase 1
Phase 1
Phase 1 trial initiation announced September 24, 2019.
GLPG1837
Cystic Fibrosis
Phase 2
Phase 2
Phase 2 top-line data released December 20, 2016.

Latest News



  1. Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV ((Euronext &amp, NASDAQ:GLPG) announces a share capital increase arising from subscription right exercises.

    Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087.

    Pursuant to the subscription right exercise program of Galapagos' management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number…




    Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from subscription right exercises.

    Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087.

    Pursuant to the subscription right exercise program of Galapagos' management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights.

    In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants) to subscribe to not yet issued securities conferring voting rights is (i) 7,018,637 subscription rights under several outstanding employee subscription right plans, which equals 7,018,637 voting rights that may result from the exercise of those subscription rights, and (ii) two subscription rights issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 25.1% and 29.9%, respectively, of the actually issued and outstanding shares after the exercise of the relevant subscription right. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

    About Galapagos

    Galapagos ((Euronext &, NASDAQ:GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

    Contacts

    Investors:

    Elizabeth Goodwin

    VP Investor Relations

    +1 781 460 1784

    Sofie Van Gijsel

    Senior Director Investor Relations

    +32 485 19 14 15

    Media:

    Carmen Vroonen

    Global Head of Communications & Public Affairs

    +32 473 824 874

    Anna Gibbins

    Senior Director Therapy Areas Communications

    +44 7717 801900

    Forward-looking statements

    This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.







    1    Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market







    Attachment

    View Full Article Hide Full Article
  2. Oxurion NV Business Update - H1 2020

    Progressing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – Beyond anti-VEGF

    Positive data from Phase 1 study evaluating THR-687, a pan-RGD integrin antagonist, for the treatment of DME

    First Patient dosed in Phase 2 (‘KALAHARI') study evaluating THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME

    Total Cash & Investments at €37.9 million as of June 30, 2020

    Highlights
                  

    • Focused on developing a diabetic macular edema (DME) franchise based on novel therapeutics with the potential to improve vision for all DME patients
       
    • DME franchise based on two innovative drug candidates, THR-149 and THR-687 with different and complementary, non-VEGF…

    Oxurion NV Business Update - H1 2020

    Progressing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – Beyond anti-VEGF

    Positive data from Phase 1 study evaluating THR-687, a pan-RGD integrin antagonist, for the treatment of DME

    First Patient dosed in Phase 2 (‘KALAHARI') study evaluating THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME

    Total Cash & Investments at €37.9 million as of June 30, 2020

    Highlights

                  

    • Focused on developing a diabetic macular edema (DME) franchise based on novel therapeutics with the potential to improve vision for all DME patients

       
    • DME franchise based on two innovative drug candidates, THR-149 and THR-687 with different and complementary, non-VEGF modes of action

       
    • First patient dosed in Phase 2 (‘KALAHARI') study evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME in September

       
    • Positive data from Phase 1 study evaluating THR-687, a pan-RGD integrin antagonist, for the treatment of DME was announced in January

       
    • Preparations for Phase 2 study with THR-687 in DME are progressing as planned. Study expected to start by mid-2021

       
    • In August, Oxurion appointed Grace Chang, M.D., Ph.D. as Chief Medical Officer to lead the company's clinical programs for THR-149 and THR-687



    Financial

                             

                                                                                                                                                                                  

          ·At the end of June 2020, Oxurion had cash, cash equivalents & investments of €37.9 million. This compares to €52.9 million at the end of December 2019.

    -----

    Conference call scheduled on September 17 at 6.30 pm CET (details at the end of the release)

    -----

    Leuven, Belgium, September 17, 2020 – 17.45 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on diabetic macular edema (DME), today issues its business and financial update for the sixth-month period ending June 30, 2020.

    Oxurion is focused on developing an industry leading DME franchise based on novel therapies designed to potentially provide improved visual outcomes for all DME patients.

    The Company is progressing its pipeline of innovative clinical drug candidates for treating DME. DME is a significant global healthcare problem and the major cause of vision loss in diabetic patients worldwide.

    Oxurion's clinical development pipeline consists of two novel products with different and complimentary, non-VEGF, modes of action:   

    • THR-149 is a potent plasma kallikrein inhibitor with the potential to become the treatment of choice for DME patients who respond sub-optimally to anti-VEGF therapy. 

       
    • THR-687 is a best in class small molecule pan-RGD integrin antagonist being developed to treat DME with the possibility to become the standard of care for all treatment-naïve DME patients.



                 

    Patrik De Haes, M.D., CEO of Oxurion, said:

    "We have made significant progress in developing our DME franchise in the first half of 2020. Following the positive Phase 1 results for THR-149 in 2019, in January we announced positive and highly promising Phase 1 results with THR-687 showing that this novel pan-RGD integrin antagonist has the potential to deliver improved visual outcomes to a broad population of DME patients when compared to anti-VEGFs, the current standard of care.

    We have recently started our Phase 2 study of THR-149 in patients with DME. This two-part study will first select the optimal dose of THR-149 and will then compare it with aflibercept in terms of improvements in best corrected visual acuity. This Phase 2 data is designed to support our plans to position THR-149 as the treatment of choice for the large number of DME patients who have a sub-optimal response to anti-VEGF therapy.

    By successfully developing THR-149 and THR-687, two novel and complimentary drug candidates that could offer improved therapeutic options beyond anti-VGEFs, we believe we are positioned to build an industry leading DME franchise. We are confident that creating this franchise will deliver significant benefits to nearly all DME patients globally and will, in parallel, generate attractive returns for our shareholders."



    Diabetic Macular Edema – Oxurion's key focus

    Diabetic macular edema (DME) is a complication of diabetes caused by fluid accumulation in the macula (central part of the retina), due to leaking blood vessels, leading to swelling of the macular area due to the increased permeability of the vessels.

    DME is a result of another complication of diabetes, called diabetic retinopathy (DR), in which blood vessels in the eye are damaged, allowing fluid to escape.  DR is the presence and characteristic evolution of typical retinal microvascular lesions in an individual with diabetes. DR is a chronic, progressive, sight-threatening, and life-altering disease, and is the leading cause of vision loss in working-age adults (20-65 years).

    DME, which is a consequence of DR, can occur at any stage in the development of DR. More than one in three people living with diabetes will develop some form of DR in their lifetime, and a third of those will have some vision-threatening form of the disease such as DME.   

    DR and DME are a growing public health concern due to the rapid growth in the number of people with diabetes globally.

    An estimated 37.8 million people have been diagnosed with diabetes in the United States (US), European top five countries (EU5) (France, Germany, Italy, Spain, and the United Kingdom), and Japan. If the undiagnosed population is included, the estimated number of people with diabetes in these countries increases to 61.3 million people.

    The prevalence of DME was estimated to be 2.8 million people in the US, EU5 and Japan in 2019. The market value for DME treatments in these markets was estimated to be between approximately $3.4 to $3.8 billion in 2019.

    The market for DME therapies is dominated by anti-VEGFs, which are the current standard of care. However, anti-VEGFs have been shown to deliver sub-optimal results in a significant portion of the patient population.  Around 40% of DME patients have an unsatisfactory early visual response with anti-VEGF therapy, and in many cases anti-VEGFs fail to achieve a clinically meaningful visual improvement. 

    Oxurion is focused on solving these unmet medical needs in DME.



    Oxurion's Emerging DME Franchise

    In general, treatment of DME is centered around anti-VEGF therapies. However, despite the significant success of anti-VEGFs, there will always be a need from both physicians and patients for improved therapies that have:

    • Treatment capabilities for the 40% of DME patients who respond sub-optimally to anti-VGEFs
    • Faster onset of action
    • Better therapeutic effect in terms of visual function, best corrected visual acuity (BCVA), and response rate (proportion of patients)
    • Longer duration of response allowing extended treatment intervals
    • Improved convenience of treatment through a simpler dosing regimen  

    Those requirements are driving the development of THR-149 and THR-687 to meet specific unmet needs in the market so that both novel compounds could become the new standard of care for patients with DME.

    Oxurion's emerging DME franchise will be based on the successful development of both THR-149 and THR-687, two novel therapeutics with different modes of action designed for specific complementary target patient groups.  Oxurion is confident that with both THR-149 and THR-687 it will be able to provide new tailored therapeutic solutions that deliver improved clinical outcomes to most DME patients.



    Oxurion's DME Pipeline

    THR-149 – a plasma kallikrein inhibitor for treatment of DME

    First patient treated in Phase 2 study evaluating THR-149 for treatment of DME.

    THR-149 is a novel plasma kallikrein inhibitor being developed as a potential new standard of care for the 40% of DME patients who respond sub-optimally to anti-VEGF therapy.

    THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, a validated target for DME.

    The Phase 1 study for THR-149 showed that it:

    • is well-tolerated and safe. No dose-limiting toxicities nor drug-related serious adverse events were reported at any of the dosages evaluated in the study.

       
    • delivered promising results in relation to efficacy, particularly improvements in the patient's BCVA. A rapid onset of action was observed from Day 1, with an increasing average improvement in BCVA of up to 7.5 letters at Day 14.

    Importantly, this activity was maintained with an average improvement in BCVA of 6.5 letters at Day 90 following a single injection of THR-149.

    Data from this positive Phase 1 study with THR-149 was presented at several major retina conferences in Europe and the US in 2019, including the European Society of Retina Specialists (EURETINA) in Paris and the Retina Society Annual Meeting in London.

    THR-149 is currently in a 2-part Phase 2 development program (‘KALAHARI' study). The first part (Part A) will evaluate 3 dose levels of THR-149 in patients with DME to select the optimal dose which will then be compared against current anti-VEGF standard of care in the form of aflibercept (Eylea) in the second part of the study (Part B). Initial data (from Part A) is expected in mid-2021.

    This novel drug candidate was generated using Bicycle Therapeutics' Bicycles® technology platform. 

    THR-687 - a small molecule pan-RGD integrin antagonist for the treatment of DME

    Positive Phase 1 Results with THR-687 for the treatment of DME – Phase 2 program expected to start in mid-2021

    Oxurion is developing THR-687, a best-in-class pan-RGD integrin antagonist, to preserve vision in a broad range of patients with DME.

    Topline data from the Phase 1 trial showed that THR-687:

    • Is well-tolerated and safe with no dose-limiting toxicities. No serious adverse events were reported at any of the doses evaluated in the study.

       
    • The study also looked at efficacy including changes to the patient's BCVA. Across all doses, a rapid onset of action as measured by mean BCVA change was observed from Day 1 with an increase of 3.1 letters, which further improved to 9.2 letters at Month 1.

       
    • This activity was maintained with a mean BCVA improvement of 8.3 letters at Month 3 following a single injection of THR-687.

       
    • A clear dose response was seen in terms of BCVA with the highest dose of THR-687 delivering a mean BCVA Improvement of 11 letters at Day 14, with a peak improvement of 12.5 letters at Month 3. 

       
    • In addition, a peak mean central subfield thickness (CST) decrease of 106 µm was observed at Day 14 with the highest dose of THR-687.

    Data from this positive Phase 1 study with THR-687 were presented by a leading retina expert at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2020 Meeting in February 2020 in Miami (US).

    Oxurion is preparing a Phase 2 study with THR-687 that is expected to start in mid-2021.



    Appointments

    In August, Oxurion appointed Grace Chang, M.D., Ph.D. as its Chief Medical Officer (effective August 1, 2020).  She will be responsible for leading the Company's clinical programs for both THR-687 and THR-149 as Oxurion looks to build a world-leading DME franchise that could provide much improved therapeutic solutions for all DME patients.

    Dr Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development.

    Dr Chang is currently an adjunct Clinical Associate Professor in the Department of Ophthalmology, Vitreoretinal Service at the University of Southern California in Los Angeles.

    In March, Oxurion also appointed Kathleen Paisley as Chief Legal Officer and Michaël Dillen as Chief Corporate Development and Corporate Secretary.

    Kathleen is an accomplished lawyer with more than 25 years' experience in major law firms practicing in Brussels, London and The Hague. She joins Oxurion from AMBOS NBGO where she was a Partner for nearly ten years. Kathleen has extensive experience with International business transactions, especially in the biotech and tech sector, regulatory compliance and EU competition law.

    Kathleen has a degree from the Yale Law School as well as an MBA in Finance from Florida Atlantic University and has passed the Certified Public Accountancy exam.

    Michaël was the Company Secretary and VP Corporate Development at Mithra Pharmaceuticals SA prior to joining Oxurion. He has 14 years of legal experience, including corporate development, corporate counsel, legal, regulatory, and company secretary activities, for pharmaceutical companies as well as at leading law firms. Previously, he was Chief Legal Officer at Terumo Corp.

    Michaël received Law degrees from the University of Antwerp and Queen Mary University of London, and a Business degree from Solvay Brussels School.



    JETREA® Marketing Authorization Being Transitioned to Inceptua Group

    In March, Oxurion announced the signing of a JETREA® global commercial license agreement with Inceptua Group.  

    The Inceptua Group is a global pharmaceutical company and service partner spanning the product lifecycle – from clinical trials, through early access programs to licensing and commercialization of products. The Group has offices in Europe, the US and Asia.

    On September 15, the Company received the final approval by the European Commission for the official transfer of the Marketing Authorization for JETREA® to Inceptua Group. This means that JETREA® is now being commercialized solely by Inceptua on a world-wide basis.  This will allow Oxurion to fully focus on further developing its DME franchise.

    Oncurious

    Pre-clinical and clinical activities are progressing as planned



    Financial Update

    During the first six months of 2020, Oxurion reported a gross profit of €0.9 million, compared to a gross profit of €0.6 million for the same period in 2019.

    Oxurion's R&D expenses were €10 million during the first half year of 2020. In the same period of 2019, the R&D expenses were €12 million.

    The incremental investments related to the start of the Phase 2 clinical study evaluating THR-149 and the work needed to prepare for the Phase 2 clinical study with THR-687 were largely offset by a €3.6 million decline in costs due to the halting of all THR-317 clinical developments, and an overall reduction of activities related to JETREA®.

    Selling and marketing expenses amounted to €1.8 million compared to €3.4 million in the corresponding period of 2019. The decrease is directly related to the discontinuation of commercial support for JETREA®.

    General and administrative expenses were €2.7 million. This compares to €3.3 million in the first half of 2019.

    For the first half of 2020, Oxurion reported a net loss of €13.3 million (or -€0.35 per share), compared to a net loss of €33.3 million for the same period in 2019. The 2019 figure included the write-off of the €16.9 million remaining JETREA® intangible assets as well as an operating/current loss of €16.4 million. 

    As of June 30, 2020, Oxurion had €37.9 million in cash, cash equivalents and investments.  This compared to €52.9 million as of the end of December 2019.

    ---

    Conference call in English is scheduled on September 17, 2020, at 6:30 p.m. CET / 5.30 p.m BST

    Webcast link to conference call:

    https://www.investis-live.com/oxurion/5f5a449faf34541200228273/teys

    Participant telephone numbers:

    Brussels: +32 (0) 2 789 8603

    Belgium Toll Free: 0800 746 68

    Standard International Access: +44 (0) 20 3003 2666

    UK Toll Free: 0808 109 0700

    USA Toll Free: 1 866 966 5335          

    Password: Oxurion

    A replay of the call will be available on Oxurion's website (www.oxurion.com) following the live event.

    END

    For further information please contact:

    Oxurion NV

    Wouter Piepers,

    Global Head of Investor Relations

    & Corporate Communications

    Tel: +32 16 75 13 10 / +32 478 33 56 32





     
    Citigate Dewe Rogerson

    David Dible/ Sylvie Berrebi/ Frazer Hall

    Tel: +44 20 7638 9571



    About Oxurion

    Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide.

    Oxurion is building a leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics:

    • THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.

      THR-149 has shown positive topline Phase 1 results for the treatment of DME.  The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.

      THR-149 was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ:BCYC)



    • THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020. THR-687 is expected to enter a Phase 2 clinical trial by mid 2021.

            THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV ((Euronext &, NASDAQ:GLPG).

    Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

    More information is available at www.oxurion.com.

    Important information about forward-looking statements

    Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.  No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

    Unaudited consolidated statement of profit and loss

    In '000 euro (for the period ended on June 30)20202019
       
    Income1,2591,807
    Sales1,2491,804
    Income from royalties103
    Cost of sales-315-1,224
    Gross profit944583
    Research and development expenses-9,005-12,040
    General and administrative expenses-2,745-3,329
    Selling expenses-1,774-3,408
    Other operating income2501,720
    Impairment losses0-16,891
    Operating result-13,230-33,365
    Finance income50236
    Finance expense-139-175
    Result before income tax-13,319-33,304
    Taxes0-7
    Loss for the period-13,319-33,311
       
    Attributable to:  
    Equity holders of the company-13,139-33,317
    Non-controlling interest-1806
       
    Result per share  
    Basic earnings/(loss) per share (euro)-0.35-0.87
    Diluted earnings/(loss) per share (euro)-0.35-0.87

    Unaudited consolidated statements of other comprehensive income

    In '000 euro (for the period ended on June 30)20202019
    Loss for the period-13,319-33,311
    Exchange differences on translation of foreign operations4829
    Other comprehensive income, net of income tax4829
    Other comprehensive income that will not be reclassified to profit or loss4829
    Total comprehensive income for the period-13,271-33,282
    Attributable to:  
    Equity holders of the company-13,091-33,288
    Non-controlling interest-1806

    Unaudited consolidated statement of financial position

    In '000 euro (as at)30-Jun-2031-Dec-19
       
    ASSETS  
    Property, plant and equipment299340
    Right-of-use assets1,7832,212
    Intangible assets2,2521,982
    Other non-current assets9696
    Non-current tax credit3,6023,385
    Non-current assets8,0328,015
    Inventories2020
    Trade and other receivables2,3543,592
    Current tax receivables274467
    Investments10,34910,444
    Cash and cash equivalents27,50942,492
    Current assets40,50657,015
    Total assets48,53865,030
       
    EQUITY AND LIABILITIES  
    Share capital100,644100,644
    Share premium00
    Cumulative translation differences-567-615
    Other reserves-11,873-12,122
    Retained earnings-47,886-34,747
    Equity attributable to equity holders of the company 40,31853,160
    Non-controlling interest-34146
    Total equity 40,28453,306
    Lease liabilities9261,335
    Non-current liabilities9261,335
    Trade payables2,5814,725
    Lease liabilities883898
    Other short-term liabilities3,8644,766
    Current liabilities7,32810,389
    Total equity and liabilities48,53865,030





    Unaudited consolidated statement of cash flows

    In '000 euro (for the period ended on June 30)20202019
       
    Cash flows from operating activities  
    Loss for the period-13,319-33,311
    Finance expense139175
    Finance income-50-236
    Depreciation of property, plant and equipment585600
    Amortization and impairment of intangible assets018,468
    Equity settled share-based payment transactions249257
    Decrease in trade and other receivables including tax receivables and inventories1,2141,036
    Decrease in short-term liabilities-3,061-4,140
    Net cash flows used (-)/ generated in operating activities-14,243-17,151
       
    Cash flows from investing activities  
    Disposal of property, plant and equipment (following a sale)2214
    Decrease / increase (-) in investments950
    Interest received and similar income044
    Purchase of property, plant and equipment-92-73
    Net cash flows used (-) / generated in investing activities-245-15
       
    Cash flows from financing activities  
    Principal paid on lease liabilities-454-407
    Interest paid on lease liabilities-9-13
    Paid interests-5-4
    Net cash flows used (-) / generated in financing activities-468-424
       
    Net change in cash and cash equivalents-14,956-17,590
    Net cash and cash equivalents at the beginning of the period42,49264,652
    Effect of exchange rate fluctuations-2763
    Net cash and cash equivalents at the end of the period27,50947,125





    Unaudited consolidated statement of changes in equity

     Share capitalShare premiumCumulative translation differencesOther reservesRetained earningsAttributable to equity holders of the companyNon-controlling interestTotal
    As at January 1, 2019137,56413-273-12,563-19,853104,888422105,310
    Loss for the period 20190000-33,317-33,3176-33,311
    Change to foreign currency translation difference and revaluation reserve00290029029
    Share-based payment transactions00025602560256
    As at June 30, 2019137,56413-244-12,307-53,17071,85642872,284
             
    As at January 1, 2020100,6440-615-12,122-34,74753,16014653,306
    Loss for the period 2020 000-13,139-13,139-180-13,319
    Change to foreign currency translation difference and revaluation reserve 0480048048
    Share-based payment transactions 0024902490249
    As at June 30, 2020100,6440-567-11,873-47,88640,318-3440,284

    Attachment

    Primary Logo

    View Full Article Hide Full Article
  3. KRAKOW, Poland, Sept. 15, 2020 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported today its 2020 H1 financial results and provided a corporate update.

    "At Ryvu, we always excelled in moving forward at a rapid pace; however, the first half of 2020 was an exceptionally eventful and intensive period for us. We have managed to achieve a couple of significant clinical milestones such as successful completion of Phase I for SEL24/MEN1703 in acute myeloid leukemia, as well as the receipt of an Orphan Drug Designation for SEL120 for the treatment of AML patients.

    "We announced a collaboration with Galapagos focused on

    KRAKOW, Poland, Sept. 15, 2020 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported today its 2020 H1 financial results and provided a corporate update.

    "At Ryvu, we always excelled in moving forward at a rapid pace; however, the first half of 2020 was an exceptionally eventful and intensive period for us. We have managed to achieve a couple of significant clinical milestones such as successful completion of Phase I for SEL24/MEN1703 in acute myeloid leukemia, as well as the receipt of an Orphan Drug Designation for SEL120 for the treatment of AML patients.

    "We announced a collaboration with Galapagos focused on the discovery and development of novel small molecule drugs in inflammation. In June, we completed the construction of the R&D Center for Innovative Drugs and subsequently moved into our new laboratories and offices. Soon afterward, we have announced our updated development strategy for 2020-2022, which was followed by the issue of series I shares and raise of over USD 36 million of new capital" - commented Pawel Przewiezlikowski, Chief Executive Officer of Ryvu.

    "We have also secured additional non-dilutive grant financing to support the development of our targeted immuno-oncology program. Despite the global pandemic, we participated in numerous scientific and business conferences presenting very good data from our early pipeline projects. What is exceptional is that we managed to do all of this and much more during the ongoing COVID-19 pandemic, including the continuation of SEL120 Phase I study in AML/MDS in the U.S.

    "The epidemiological situation required us to adopt numerous preventive measures across our entire organization to keep our scientists safe and, at the same time, assure business continuity. I believe we passed that test with flying colors, and I am proud of the work we have done at Ryvu in these six months" – adds Przewiezlikowski.

    Recent Achievements

    • On February 21, Ryvu signed a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept. This grant provides Ryvu with almost USD 8.3 million of non-dilutive financing to discover, develop, and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches. The total net value of the project amounts to USD 14 million, and the anticipated project duration is until December 2023.

     

    • On March 5, Menarini Group announced the successful completion of Phase I clinical study of SEL24/MEN1703 in Acute Myeloid Leukemia, which entitled Ryvu to receive a USD 1.96 million milestone payment. The full data from the study was be presented as a poster "Results of the dose escalation part of DIAMOND trial (CLI24-001): First-in-human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia" during the Virtual 25th EHA Congress taking place June 11-21. Throughout the dose escalation part, SEL24/MEN1703 showed an acceptable safety profile up to the recommended dose established at 125 mg/day (14 days ON – 7 days OFF in 21-days cycles). Initial evidence of single agent efficacy was observed with 1 CR and 1 CRi in elderly patients who had exhausted standard therapeutic options. A cohort Expansion study planned in relapsed/refractory AML patients in the United States and Europe, including Poland, will further investigate the single agent activity and the safety profile of SEL24/MEN1703.

     

    • On March 27, the U.S. Food and Drug Administration (FDA) granted an orphan drug designation (ODD) to Ryvu's SEL120 for the treatment of patients with acute myeloid leukemia (AML).

     

    • On April 15, Galapagos NV ((Euronext &, NASDAQ:GLPG) and Ryvu Therapeutics announced a collaboration focused on the discovery and development of novel small molecule drugs in inflammation. Ryvu will contribute its biology and chemistry platform as well as related intellectual property to the program. During the joint research collaboration, Ryvu is responsible for early drug discovery, and Galapagos will be responsible for all further development of the program.

     

    • On June 2, Ryvu obtained the occupancy permits for its newly built R&D Center for Innovative Drugs, meaning it has completed the construction of the facility. Subsequently, Ryvu has initiated its move to the new headquarters.

     

    • On June 3, NodThera, Ryvu spin-off company, secured GBP 44.5 million (USD 54.5 million) Series B financing. NodThera was founded by Epidarex Capital and Ryvu in 2016 based on world class research on NLRP3 inflammasome conducted at Ryvu (at that time Selvita) in 2012-2016. The Company focused on the development of inflammasome inhibitors has already raised over GBP 80.8 million (over USD 100 million) in three funding series. After the full completion of Series B capital increase, Ryvu owns 4.8% in NodThera.

     

    • On June 4, Ryvu signed a grant agreement for the development of targeted immuno-oncology therapy, which provides Ryvu with almost USD 5.6 million of non-dilutive financing to discover, develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches. The total net value of the project amounts to over USD 8.9 million, and the anticipated project duration is until December 2023.

     

    • On June 15, Ryvu announced its updated development strategy for 2020-2022, which assumes, i.a.: completing Phase I clinical development of SEL120 in AML/MDS by the end of 2022, expanding therapeutic potential for SEL120 in solid tumors and launching a new Phase I study in selected indications in parallel to the ongoing hemato-oncology studies, advancing at least one program into the Phase I of clinical trials from preclinical pipeline.

    Important milestones in 2020, before the report date

    • On July 22, the Extraordinary General Meeting of Ryvu Therapeutics' Shareholders has decided to issue up to 2,384,245 Series I ordinary bearer shares, with the exclusion of pre-emptive rights. The share issue constituted up to 15 percent of the current Company's share capital. As a result, Ryvu Therapeutics raised over USD 36 million. Proceeds from the share issue will be allocated primarily to the Company's R&D programs.

     

    In H1 2020, Ryvu Therapeutics participated and presented at several scientific and investor conferences, including AACR 2020 Virtual Annual Meeting, Virtual 25th Annual European Hematology Association (EHA) Congress, Jefferies 2020 Virtual Healthcare Conference, BIO Digital 2020, Solebury Trout Investor Access during JP Morgan 2020, Solebury Trout Virtual Investor Conference, BIO-Europe Spring 2020 and 32nd Annual ROTH Conference.

    Ryvu 2020 Half-Year Financial Results

    In the first half of 2020, Ryvu Therapeutics noted a 38%* increase in its revenues, up to PLN 24.5 million (USD 6.1 million). Revenues from partnering contracts have increased from PLN 1.9 million (USD 0.5 million ) in H1 2019, up to PLN 14.7 million (USD 3.7 million ) in H1 2020.

    Operational costs related in majority to the research and development expenditures amounted in H1 2020 to PLN 36.3 million (USD 9.1 million), as compared to PLN 38.7 million (USD 10.2 million) in the same period last year. Operational loss has decreased and amounted to PLN 11.8 million (USD 3.0 million), compared to PLN 21 million (USD 5.5 million) in H1 2019.

    On June 30, 2020, Ryvu Therapeutics held PLN 38.5 million  (USD 9.7 million) in cash, cash equivalents, and short-term investments. On September 10, the balance, following the share issue, amounted to PLN 176.9 million (USD 44.4 million).

    *Percentage changes in the press release are calculated based on the functional currency [PLN].



    About Ryvu Therapeutics

    Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets. SEL120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase 1b clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The second clinical program of Ryvu is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia.

    Other Ryvu programs developed through internal discovery platform are focused on new oncology targets in kinases, synthetic lethality, immuno-oncology and immunometabolism.

    The Company was founded in 2007 (until 2019 operating under the name Selvita S.A.) and currently employs more than 150 associates, including more than 80 PhDs. Ryvu is headquartered in Krakow, Poland. Ryvu Therapeutics is listed on the main market of the Warsaw Stock Exchange, and has been a component of sWIG80 index since March 2017. For more information, please see www.ryvu.com.

    Forward-Looking Statements

    This release may contain forward-looking statements, including, among other things, statements regarding the guidance from management, financial results, timing and/or results of clinical studies, timing of the corporate split into two companies and interaction with regulators. Ryvu cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial conditions, performance or achievements of Ryvu, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Ryvu's results, performance, financial conditions, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that Ryvu's expectations regarding development programs may be incorrect, the inherent uncertainties associated with competitive developments, clinical study and projects development activities and regulatory approval requirements, Ryvu's reliance on collaborations with third parties, and estimating the commercial potential of its development programs and Ryvu's plans regarding the corporate split and in particular its timing. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Ryvu expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

    Contacts:

    Natalia Baranowska (corporate)

    +48 784 069 418

    Julia Balanova (investors)

    +1 646 378 2936

    Cision View original content:http://www.prnewswire.com/news-releases/ryvu-therapeutics-reports-2020-half-year-financial-results-301131514.html

    SOURCE Ryvu Therapeutics

    View Full Article Hide Full Article
  4. Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

    Oxurion to Host Conference Call following the H1 Financial Results       

           
           
    Leuven, Belgium, 11 September 2020 – 08.15 A.M. CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies, with a focus on diabetic macular edema (DME), announces that the Company will issue its Business Update and First Half Financial Results on Thursday, September 17, 2020 at 5.45 p.m. CET.

    Following the announcement, Oxurion's management will host a conference call in English on Thursday, September 17 at 6.30 p.m. CET to discuss the Business Update, its Financial Results and to provide…

    Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

    Oxurion to Host Conference Call following the H1 Financial Results       

           

           

    Leuven, Belgium, 11 September 2020 – 08.15 A.M. CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies, with a focus on diabetic macular edema (DME), announces that the Company will issue its Business Update and First Half Financial Results on Thursday, September 17, 2020 at 5.45 p.m. CET.

    Following the announcement, Oxurion's management will host a conference call in English on Thursday, September 17 at 6.30 p.m. CET to discuss the Business Update, its Financial Results and to provide an overview of the progress and potential of the Company's emerging DME Franchise.

    Oxurion's First Half 2020 Conference Call & Webcast Details:

    Date: Thursday, September 17, 2020

    Time: 6.30 p.m. CET / 5.30 p.m. BST

    Participant telephone numbers:

    Brussels: +32 (0) 2 789 8603

    Belgium Toll Free: 0800 746 68

    Standard International Access: +44 (0) 20 3003 2666

    UK Toll Free: 0808 109 0700

    USA Toll Free: 1 866 966 5335    

    Password: Oxurion

    There will be a live listen-only webcast of the event, accessible from the Oxurion website.

    https://www.oxurion.com/news-events

    An on-demand version of the event will also be made available shortly after the event has finished.

    END

    For further information please contact:

    Oxurion NV

    Wouter Piepers,

    Global Head of Investor Relations

    & Corporate Communications

    Tel: +32 16 75 13 10 / +32 478 33 56 32

    Citigate Dewe Rogerson

    David Dible/ Sylvie Berrebi/Frazer Hall

    Tel: +44 20 7638 9571

    About Oxurion

    Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation, standard of care therapies to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide.

    Oxurion is building a leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics:

    •   THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.

    THR-149 has shown positive topline Phase 1 results for the treatment of DME.  The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.

    THR-149 was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ:BCYC)

    • THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020. THR-687 is expected to enter a Phase 2 clinical trial by mid-2021. 

    THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV ((Euronext &, NASDAQ:GLPG).

    Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

    More information is available at www.oxurion.com.

    Important information about forward-looking statements

    Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.  No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

    Primary Logo

    View Full Article Hide Full Article
  5.   

    Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV ((Euronext &amp, NASDAQ:GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc).

    Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.   

      600 mg ziritaxestat,
    n=21
    placebo,
    n=12
    Mean baseline mRSS (standard deviation) 27.0 (8.8) 22.5 (6.2)
    Mean change from baseline (standard error) at Week 24, p-value1 -8.3 (1.2), p=0.0411 -5.7 (1.7)

    NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept…

      

    Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc).

    Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.   

      600 mg ziritaxestat,

    n=21
    placebo,

    n=12
    Mean baseline mRSS (standard deviation) 27.0 (8.8) 22.5 (6.2)
    Mean change from baseline (standard error) at Week 24, p-value1 -8.3 (1.2), p=0.0411 -5.7 (1.7)

    NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept trial evaluating the efficacy, safety and tolerability of ziritaxestat (GLPG1690) in 33 patients with dcSSc. DcSSc is a severe autoimmune disease with one of the highest mortality rates among rheumatic diseases2 with no drugs currently approved to treat the overall disease. Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).

    Patients recruited for NOVESA included mostly females (70%) around 50 years old, with a mean disease duration of 1.9 years. Most patients enrolled were on a background immunosuppressant therapy during the course of the study.

    Ziritaxestat was generally well tolerated. No deaths were reported in this study. Two patients taking ziritaxestat experienced serious adverse events versus one patient in the placebo group. Both patients in the ziritaxestat group recovered fully and are still participating in the long-term extension trial.

    94% of patients (31 of the 33) who completed the NOVESA trial continued in the long-term open label extension trial.

    "We are excited to see that after showing promising activity in the phase 2 FLORA trial in idiopathic pulmonary fibrosis, ziritaxestat achieved statistically significant improvements in mRSS in diffuse SSc, the primary endpoint in the NOVESA study. Keeping in mind that this is our first study in SSc and that the impact on skin is difficult to measure on a background treatment with immunosuppressants, we are pleased with the results reported today. We will now further analyze the NOVESA data to determine next steps in SSc, a disease with important unmet medical need," said Dr Walid Abi-Saab, Chief Medical Officer of Galapagos.

    Detailed results from the NOVESA trial will be presented at future medical conferences.

    Ziritaxestat is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.

    About ziritaxestat

    Ziritaxestat is a small molecule, selective autotaxin inhibitor co-developed with Gilead Sciences, Inc. as part of the global collaboration between Galapagos & Gilead. Autotaxin is the main enzyme responsible for lysophosphatidic acid (LPA) production. LPA is a well-known pro-fibrotic and pro-inflammatory lipid, acting through at least 6 g-protein coupled receptors. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule ziritaxestat as an inhibitor of this target. Ziritaxestat has orphan drug designation from the US and EU in both idiopathic pulmonary fibrosis (IPF) and SSc and is currently being studied in a global Phase 3 program in IPF (ISABELA), in addition to the ongoing NOVESA extension trial.  

    For more information about ziritaxestat: www.glpg.com/glpg-1690

    For information about the studies with ziritaxestat in systemic sclerosis: www.clinicaltrials.gov

    About Galapagos

    Galapagos ((Euronext &, NASDAQ:GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

    Contacts

    Investors:

    Elizabeth Goodwin

    VP Investor Relations

    +1 781 460 1784

    Sofie Van Gijsel

    Senior Director Investor Relations

    +32 485 191415

    Media:

    Carmen Vroonen

    Global Head Communications & Public Affairs

    +32 473 824 874

    Anna Gibbins

    Senior Director Therapeutic Areas Communications

    +44 7717 801900

    Forward-looking statements

    This release may contain forward-looking statements, including, among other things, statements regarding Galapagos' strategic ambitions, the mechanism of action and potential activity of ziritaxestat the anticipated timing of clinical trials with ziritaxestat, the progression and results of such trials, future regulatory submissions and Galapagos' interactions with regulatory authorities. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that Galapagos' expectations regarding its ziritaxestat development program may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos' ongoing clinical research programs may not support registration or further development of ziritaxestat due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for ziritaxestat, Gilead), and estimating the commercial potential of ziritaxestat. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.




     

    1 P-value calculated based on least square means

    2 Nikpour et al. Curr Opin Rheumatol. 2014

    3 GlobalData

    4 Europe includes FR, DE, IT, ES, UK only





     

     

    Attachment

    View Full Article Hide Full Article
View All Galapagos NV News